Pharmacokinetic Impact of SLCO1A2 Polymorphisms on Imatinib Disposition in Patients With Chronic Myeloid Leukemia

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

(2010) Naoto Takahashi et al.   JOURNAL OF HUMAN GENETICS

Intestinal Absorption of HMG-CoA Reductase Inhibitor Pravastatin Mediated by Organic Anion Transporting Polypeptide

(2010) Yoshiyuki Shirasaka et al.   PHARMACEUTICAL RESEARCH

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

(2010) Ruben C. Hartkoorn et al.   Pharmacogenetics and Genomics

Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia

(2009) Tatsuya Kawaguchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Pharmacogenetics of the organic anion transporting polypeptide 1A2

(2009) Ryan M Franke et al.   PHARMACOGENOMICS

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs

(2008) Kazuya Maeda et al.   Drug Metabolism and Pharmacokinetics

Inhibition of Imatinib Transport by Uremic Toxins During Renal Failure

(2008) Ryan M. Franke et al.   JOURNAL OF CLINICAL ONCOLOGY